17th International Mass Spectrometry Conference :: Prague, 2006
> Go to contents (site navigation)
|Presentation date:||Mon, Aug 28, 2006|
|Presentation time:||14:30 – 16:00|
Jiyoung Kim1,2, Jong Suk Lee1, Sooyeon Park1, Kyungyun Cho3, Jung-Hoon Yoon1, Dai-Eun Sok2, Choong-Hwan Lee11 Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea
Correspondence address: Jiyoung Kim, Korea Research Institute of Bioscience and Biotechnology, 52 Eoeun-dong, Yuseong-gu, Daejeon, 305-333 Korea.
Keywords: Antibiotics; Mass Spectrometry, Liquid Chromatography; Metabolic Profiling; MS/MS.
Novel aspect: Chemotaxonomical screening approach for metabolomics.
To searching useful natural products, screening of microorganisms may increase the chance to obtain novel metabolites. Among a number of bacteria, Myxobacteria are reported to be prolific producer of a variety of bioactive secondary metabolites including antibacterial antifungal compounds. Furthermore, secondary metabolites from myxobacteria often show structural elements which are rarely produced by other sources.
In this study, to screen for new metabolites, we applied a chemotaxonomical method combined with LC-MS technique to a collection of 1,200 wild-type myxobacterial strains, most of the collected strains at the MicroBank (www.microbank.re.kr) of KRIBB, which have been characterized following analysis of 16S rRNA genes and assigned at the genus level. Metabolites were extracted from the myxobacterial strains selected through preliminary antibiotic assay and phylogenetic grouping. By comparative analysis of using the LC-MS metabolite profiles, one strain, designated Stigmatella KYC1019, showing a distinctively different profile from them, was finally selected as a representative. Metabolites of Stigmatella KYC1019 were analyzed throughout a metabolite profiling after background subtraction using Metabolite ID 2.0. A sum of 10 metabolites were identified to the previously reported compound (5) and unknown (5) using a myxobacterial metabolite database. So, we purified one, showing antimicrobial activity, of the unknown compound which was structurally identified as coriolate.
1. H. Reichenbach, Drug discovery from nature 419, (1999).
2. S. Frykman, H. T., Jorge Galazzo, J. Ind. Microbial. Biotechnol. 33, 445 (2006).
3. S. G. Villas-Boas, S. M., Mats Aekesson, J. Smedsgaard and J. Nielsen, Mass Spectrom. Rev. 24, 613 (2005).
4. Erko Stackebrandt, Orsola Pauker, Marcel Erkard,Curr. Microbiol. 50, 71 (2005).